wdi: DOPAMINE
WDI  cabinet status help  preferences A-Z search prev next
structure   (similar, related) approved names
DXRN:DOPAMINE
DPN:DOPAMINE
CAS:51-61-6
DRN:DOPAMINE
USAN:DOPAMINE
INN:DOPAMINE
DCIT:DOPAMINA
BAN:DOPAMINE
DCF:DOPAMINE
JAN:DOPAMINE

Pharmacology

Pharmacological activity:   DOPAMINERGICS; PROLACTIN-ANTAGONISTS; SYMPATHOMIMETICS-ALPHA; SYMPATHOMIMETICS-BETA
Mechanism of action:   DOPAMINERGIC; PROLACTIN-ANTAGONIST; SYMPATHOMIMETIC-ALPHA; VASODILATOR; increases glomerular filtration rate; increases systolic B.P.; mesenteric blood-flow may increase; produces mesenteric vasodilatation; noradrenaline precursor; releases noradrenaline stores natriuretic; produces renal vasodilatation; inotropic effect on the myocardium resulting in increased cardiac-output; increases pulse-pressure peripheral blood-flow may decrease; increased urinary output is not associated with decreased urinary osmolality.; acts directly and indirectly on alpha adrenergic-receptors and beta-1 adrenergic-receptors; SYMPATHOMIMETIC-BETA; HYPERTENSIVE
Indications & usage:   Myocardial-infarction; low cardiac-output; trauma; open-heart-surgery; impending renal-failure.; endotoxic sepsis; cardiac-failure; chronic cardiac-decompensation
Precautions & warnings:   Pregnancy; cyclopropane; glucose solutions without electrolytes should not be administered simultaneously with blood through the same infusion set; inject into a large vein if possible; peripheral vascular-disease; monitor with history of peripheral vascular-disease for signs of compromized circulation to the extremitiesss; use glucose solutions with care in diabetics; safety and efficacy in children have not been established; halogenated hydrocarbon anesthetics; decrease infusion-rate in event of a disproportionate increase in diastolic pressure and observe for further evidence of predominant vasoconstriction unless this is desired.; correct hypovolemia if necessary prior to treatment; children; avoid extravasation; begin treatment with one-tenth of the usual dose in those who have been treated with MAO-inhibitors
Contraindications:   Pheochromocytoma; uncorrected tachyarrhythmia; uncorrected ventricular fibrillation.
Adverse effects:   Ectopic-beats; GI-disorder; arrhythmia; azotemia.; angina-pectoris; bradycardia; cardiopathy; dyspnea; hypotension; hypertension; vomiting; vasoconstriction; vascular-disease; tachycardia; piloerection; palpitations; nausea; coronary-disease; widened QRS-complex; cardiac-conduction-disorder
Interactions:   Cyclopropane; halogenated hydrocarbon anesthetics.; potassium-free solutions; MAO-inhibitors

Registered trade names

trade namecompanycountry
DOPAMINNAFNorway
DOPAMINENATIVELLEFrance
DOPAMINE-200LUCIENFrance
DOPAMINE-50PIERRE-FABREFrance

Other names

APRICAL-DOPAMINA
CARDIOSTERIL
CATHERINE
CORDODOPA
CRIPTAN
DIHYDROXYPHENYLETHYLAMINE
DOCARD
DOFAMIN
DOMAR
DOMININ
DOPAMEX
DOPAMINEX
DOPASTAT
DOPMIN
DYNATRA
GILUDOP
HETTYTROPIN
HYDROXYTYRAMINE
INOBAN
INOTROPIN
INOVAN
INTROPIN
KAKODIN
REVIMINE
REVIVAN
SEMINIET
TENSAMIN
TRONJIN

Update information and references

Appeared: 1990.1
Updated:2003.3
peek

Metaphorics LLC wdi 4.83